<DOC>
	<DOCNO>NCT02649582</DOCNO>
	<brief_summary>In phase I/II trial , primary objective determine overall progression-free survival patient newly diagnose glioblastoma autologous Wilms ' tumor 1 ( WT1 ) messenger ( ) RNA-loaded dendritic cell ( DC ) vaccination add adjuvant temozolomide maintenance treatment follow ( sub ) total resection temozolomide-based chemoradiation .</brief_summary>
	<brief_title>Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide Glioblastoma Patients</brief_title>
	<detailed_description>Glioblastoma multiforme ( GBM ) , microscopically infiltrative disease , common malignant brain tumor worldwide . Despite optimized standard care treatment median survival prognosis remain poor median survival 15 % five year survival diagnosis 5 % . In single arm single centre phase I/II trial investigator determine overall progression free survival patient newly diagnose GBM autologous WT1 mRNA load dendritic cell vaccination add standard care treatment . During two year recruitment investigator include 20 patient newly diagnose , histologically verify glioblastoma ( WHO grade IV ) receive total subtotal resection tumor . Patients underwent prior radiation chemotherapy history malignancy exclude . In addition standard care consist adjuvant chemoradiation temozolomide temozolomide maintenance patient receive intradermal vaccination autologous WT1 mRNA-loaded dendritic cell commence 1 week radiotherapy . The dendritic cell therapy product generate administered Antwerp University Hospital , specifically Center Cell Therapy Regenerative Medicine ( CCRG ) Division Hematology , head Prof. Zwi Berneman . Recruitment begin December 2015 . After 2 year follow overall progression free survival analysis perform compare publish data standard care treatment without vaccination . In addition investigator look feasibility , incidence adverse event immunogenicity .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Newly diagnose , histologically verify glioblastoma ( WHO grade IV ) Aged ≥ 18 year Total subtotal resection : Total resection : macroscopic complete resection assess neurosurgeon absence residual contrastenhancing mass postoperative ( ≤ 72h ) brain MRI Subtotal resection : macroscopic complete resection assess neurosurgeon , residual contrastenhancement ≤ 2 cm³ postoperative ( ≤ 72h ) brain MRI Signed informed consent Willing able comply protocol judge Investigator Estimated start chemoradiation ≥ 28 day ≤ 49 day follow surgical resection Adequate hematologic , renal , hepatic function time screening : Hemoglobin ≥ 10 g/dL ( transfusion allow maintain exceed level ) Monocyte count ( Mo ) ≥ 0.2 x 10^9/L Absolute neutrophil count ( ANC ) ≥ 1.0 x 10^9/L Platelet count ( PLT ) ≥ 100 x 10^9/L Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) Liverfunction value &lt; 3 x ULN No corticosteroid treatment ≤ 1 week apheresis WHO performance status ≤ 2 Life expectancy ≥ 3 month estimate Investigator History another malignancy , except adequately control basal cell skin carcinoma , squamous skin carcinoma , carcinoma situ uterine cervix Prior radiation chemotherapy Any preexisting contraindication temozolomide treatment Any preexisting contraindication contrastenhanced brain MRI Pregnant breastfeeding Documented immune deficiency systemic immunesuppressive treatment Positive viral serology HIV , HBV , HCV , syphilis time screen Any condition , either physical psychological , reasonable suspicion thereof clinical special investigation , contraindicate use vaccine , may negatively affect patient compliance , may place patient high risk potential treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Dendritic cell</keyword>
	<keyword>Chemoimmunotherapy</keyword>
	<keyword>Adjuvant therapy</keyword>
</DOC>